Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jviromet.2021.114222 http://scihub22266oqcxt.onion/10.1016/j.jviromet.2021.114222 34197839!8239204!34197839     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Virol+Methods 2021 ; 296 (ä): 114222 Nephropedia Template TP {{tp|p=34197839|t=2021. Evaluation of spike protein antigens for SARS-CoV-2 serology |pdf=|usr=}}{{34197839}} gab.com Text Evaluation of spike protein antigens for SARS-CoV-2 serology JO: J Virol Methods http://www.kidney.de/pget.php?&tw=1&pmid=34197839 #FOAvip BACKGROUND: Spike protein domains are being used in various serology-based assays to detect prior exposure to SARS-CoV-2 virus. However, there has been limited comparison of antibody titers against various spike protein antigens among COVID-19 infected patients. METHODS: We compared four spike proteins (RBD, S1, S2 and a stabilized spike trimer (ST)) representing commonly used antigens for their reactivity to human IgG antibodies using indirect ELISA in serum from COVID-19 patients and pre-2020 samples. ST ELISA was also compared against the EUROIMMUN IgG ELISA test. Further, we estimated time appropriate IgG and IgA seropositivity rates in COVID-19 patients using a panel of sera samples collected longitudinally from the day of onset of symptoms (DOS). RESULTS: Among the four spike antigens tested, the ST demonstrated the highest sensitivity (86.2 %; 95 % CI: 77.8-91.7 %), while all four antigens showed high specificity to COVID-19 sera (94.7-96.8 %). 13.8 % (13/94) of the samples did not show seroconversion in any of the four antigen-based assays. In a double-blinded head-to-head comparison, ST based IgG ELISA displayed a better sensitivity (87.5 %, 95 % CI: 76.4-93.8 %) than the EUROIMMUN IgG ELISA (67.9 %, 95 % CI: 54.8-78.6 %). Further, in ST-based assays, we found 48 % and 50 % seroconversion in the first six days (from DOS) for IgG and IgA antibodies, respectively, which increased to 84 % (IgG) and 85 % (IgA) for samples collected >/=22 days from DOS. CONCLUSIONS: Comparison of spike antigens demonstrates that spike trimer protein is a superior option as an ELISA antigen for COVID-19 serology. Twit Text FOAVip Evaluation of spike protein antigens for SARS-CoV-2 serology ????J Virol Methods http://www.kidney.de/pget.php?&tw=1&pmid=34197839 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34197839 #FOAvip English Wikipedia <ref>{{Cite pmid|34197839}}</ref> Evaluation of spike protein antigens for SARS-CoV-2 serology #MMPMID34197839 Jagtap S; K R; Valloly P; Sharma R; Maurya S; Gaigore A; Ardhya C; Biligi DS; Desiraju BK; Natchu UCM; Saini DK; Roy R J Virol Methods 2021[Oct]; 296 (ä): 114222 PMID34197839show ga BACKGROUND: Spike protein domains are being used in various serology-based assays to detect prior exposure to SARS-CoV-2 virus. However, there has been limited comparison of antibody titers against various spike protein antigens among COVID-19 infected patients. METHODS: We compared four spike proteins (RBD, S1, S2 and a stabilized spike trimer (ST)) representing commonly used antigens for their reactivity to human IgG antibodies using indirect ELISA in serum from COVID-19 patients and pre-2020 samples. ST ELISA was also compared against the EUROIMMUN IgG ELISA test. Further, we estimated time appropriate IgG and IgA seropositivity rates in COVID-19 patients using a panel of sera samples collected longitudinally from the day of onset of symptoms (DOS). RESULTS: Among the four spike antigens tested, the ST demonstrated the highest sensitivity (86.2 %; 95 % CI: 77.8-91.7 %), while all four antigens showed high specificity to COVID-19 sera (94.7-96.8 %). 13.8 % (13/94) of the samples did not show seroconversion in any of the four antigen-based assays. In a double-blinded head-to-head comparison, ST based IgG ELISA displayed a better sensitivity (87.5 %, 95 % CI: 76.4-93.8 %) than the EUROIMMUN IgG ELISA (67.9 %, 95 % CI: 54.8-78.6 %). Further, in ST-based assays, we found 48 % and 50 % seroconversion in the first six days (from DOS) for IgG and IgA antibodies, respectively, which increased to 84 % (IgG) and 85 % (IgA) for samples collected >/=22 days from DOS. CONCLUSIONS: Comparison of spike antigens demonstrates that spike trimer protein is a superior option as an ELISA antigen for COVID-19 serology. |Antibodies, Viral/blood/immunology[MESH] |Antigens, Viral/blood/*immunology[MESH] |COVID-19 Serological Testing/*methods[MESH] |COVID-19/blood/*diagnosis/immunology[MESH] |Enzyme-Linked Immunosorbent Assay/methods[MESH] |Humans[MESH] |Immunoglobulin A/blood/immunology[MESH] |Immunoglobulin G/blood/immunology[MESH] |SARS-CoV-2/*immunology[MESH] |Sensitivity and Specificity[MESH] |Seroconversion[MESH]Evaluation of spike protein antigens for SARS-CoV-2 serology (epmc).pdf DeepDyve Pubget Overpricing